Tovaxin™

Parent company: Opexa Therapeutics.

T-cell vaccine given via subcutaneous injections every four weeks.

Works similarly to a vaccine for a virus or bacteria; myelin-attacking cells are removed from a small amount of the patient's blood; these cells are inactivated and then injected back into the patient; the immune system is stimulated to potentially recognize and eliminate the inactivated cells and the same attacking cells not removed from the blood.

TERMS is a placebo-controlled study being conducted at 40 sites in the United States with CIS and RRMS patients.

Recruitment of 150 patients for this phase IIb study expected to be complete by mid-year (2007).

TERMS is one of three ongoing studies using the current vaccine Patients completing the one-year trial may participate in an open-label, one-year extension study where all patients would receive Tovaxin.